Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study
Metadata
Show full item recordEditorial
MDPI
Materia
Pre-diagnostic resistin Colorectal cancer Risk Prospective Inflammation
Date
2022-11-09Referencia bibliográfica
Pham, T.-T... [et al.]. Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study. Cancers 2022, 14, 5499. [https://doi.org/10.3390/cancers14225499]
Sponsorship
World Health Organization; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London; Danish Cancer Society; Ligue contre le Cancer (France); Institut Gustave Roussy (France); Mutuelle Generale de l'Education Nationale (France); Institut National de la Sante et de la Recherche Medicale (Inserm); Deutsche Krebshilfe; Federal Ministry of Education & Research (BMBF); Hellenic Health Foundation (Greece); Fondazione AIRC per la ricerca sul cancro; Consiglio Nazionale delle Ricerche (CNR); Netherlands Government Netherlands Government; World Cancer Research Fund International (WCRF); Netherlands Government; Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Instituto de Salud Carlos III; Junta de Andalucia; Principality of Asturias; Regional Government of Basque Country (Spain); Regional Government of Murcia (Spain); Regional Government of Navarra (Spain); Instituto de Salud Carlos III RD06/0020; Swedish Cancer Society; Swedish Scientific Council (Sweden); Regional Government of Skane and Vasterbotten (Sweden); UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Cancer Research UK; Netherlands Government; Deutsches Krebsforschungszentrum (Germany) ERC-2009-AdG 232997Abstract
Resistin is a polypeptide implicated in inflammatory processes, and as such could be
linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found
in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the
association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic
resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and
Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293
incidence density-matched controls. Conditional logistic regression models controlled for matching
factors (age, sex, study center, fasting status, and women-related factors in women) and potential
confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist
circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs)
for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling
resistin, 1.11; 95% CI 0.94–1.30; p = 0.22). There were also no associations with CRC subgroups
defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC
risk among participants followed-up maximally two years, but not among those followed-up after
more than two years. We observed no substantial correlation between baseline circulating resistin
concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin),
or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein
cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there
was little evidence of an association between baseline circulating resistin concentrations and CRC
risk in European men and women.